相关实验视频

Updated: May 28, 2025

Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)

Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)

Published on: January 10, 2025

骨髓氧化酶作为阿尔茨海默病中氧化损伤的治疗点

Astrid Mayleth Rivera Antonio¹, Itzia Irene Padilla Martínez², Mónica A Torres-Ramos³

¹Laboratorio de Biofísica y Biocatálisis, Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Salvador Díaz Mirón s/n, MéxicoCiudad de México, México.

Journal of enzyme inhibition and medicinal chemistry

|February 14, 2025

概括

骨髓氧化酶 (MPO) 通过增加氧化应激和神经炎症,有助于阿尔茨海默病 (AD) 的进展. 抗MPO抑制剂在阿尔茨海默病治疗中显示出治疗潜力.

科学领域:

神经科学是一个神经科学.
生物化学生物化学

背景情况:

阿尔茨海默病 (AD) 是一种流行的神经退行性疾病,与粉样β (Aβ) 病理学有关.
与血管的Aβ相互作用可以破坏血脑屏障 (BBB),导致神经炎症和氧化应激.

研究的目的:

审查骨髓氧化酶 (MPO) 在阿尔茨海默病进展中的作用.
调查MPO对AD中氧化应激和神经炎症的贡献.
探索MPO作为潜在的生物标志物,并评估MPO抑制剂用于AD治疗.

主要方法:

文献综述专注于MPO在AD病变发生过程中的作用.
对MPO参与氧化应激和神经炎症的分析.
在AD模型中评估针对MPO的治疗策略.

主要成果:

通过透中性粒细胞或微质细胞释放的MPO产生低酸 (HOCl),加剧氧化应激.
在AD中,MPO活性与神经血管损伤和BBB中断相关.
抗MPO抑制剂显示出减轻AD相关神经毒性的潜力.

结论:

通过氧化应激和神经炎症,MPO在AD病变发生过程中发挥着重要作用.
抗MPO抑制剂,特别是双作用剂,代表了阿尔茨海默病的有前途的治疗途径.
MPO具有作为AD进展的诊断生物标志物的潜力.

关键词:

阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.骨髓氧化酶是什么?含有低酸的酸盐.氧化应激是一种氧化应激.

更多相关视频

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

Correlative Light and Electron Microscopy to Study Microglial Interactions with β-Amyloid Plaques

Correlative Light and Electron Microscopy to Study Microglial Interactions with β-Amyloid Plaques

Published on: June 1, 2016

相关概念视频

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...